RecruitingPhase 3NCT07023302

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Studying Alopecia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AbbVie
Principal Investigator: ABBVIE INC.
AbbVie
Intervention: Upadacitinib(drug)
Enrollment: 123 enrolled
Eligibility: 12-63 years · All sexes
Timeline: 2025 – 2029

Study locations (15)

Nagoya City University Hospital /ID# 275409, Nagoya, Aichi-ken, Japan
Kurume University Hospital /ID# 275519, Kurume-shi, Fukuoka, Japan
Kanazawa Medical University Hospital /ID# 275521, Kahoku-gun, Ishikawa-ken, Japan
Nagomi Dermatology Clinic /ID# 275418, Ebina-shi, Kanagawa, Japan
Rifu Dermatology Allergy Clinic /ID# 274875, Miyagi-gun, Miyagi, Japan
Tohoku University Hospital /ID# 274931, Sendai, Miyagi, Japan
Niigata University Medical & Dental Hospital /ID# 274775, Niigata, Niigata, Japan
Shinsaibashi Inui Dermatology Clinic /ID# 274851, Osaka, Osaka, Japan
Osaka Metropolitan University Hospital /ID# 274956, Osaka, Osaka, Japan
Hamamatsu University Hospital /ID# 274639, Hamamatsu, Shizuoka, Japan
Kyorin University Hospital /ID# 274882, Mitaka-shi, Tokyo, Japan
Tokyo Medical University Hospital /ID# 274844, Shinjuku-ku, Tokyo, Japan
Keio University Hospital /ID# 275640, Shinjuku-ku, Tokyo, Japan
Yamaguchi University Hospital /ID# 274638, Ube, Yamaguchi, Japan
Juntendo Tokyo Koto Geriatric Medical Center /ID# 275424, Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07023302 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia →

← Back to all trials